Xu Haiyan, Nuamah Isaac, Liu Jingyi, Lim Pilar, Sampson Allan
Clinical Biostatistics, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Titusville, NJ 08560, USA.
Pharm Stat. 2009 Oct-Dec;8(4):301-16. doi: 10.1002/pst.358.
This paper proposes a Dunnett-Bonferroni-based parallel gatekeeping procedure in a setting of dose-response clinical trials with multiple endpoints. It follows the Dunnett-based parallel gatekeeping strategy of Dmitrienko et al. (Pharm. Stat. 2006; 5:19-28), but differs in the calculation of the critical values. The implementation of the Dunnett-based parallel gatekeeping procedure relies on assumptions difficult to justify in typical clinical trials, namely (a) that the joint distribution of the test statistics from different endpoints can be approximated by a multivariate-t distribution and (b) that the true correlation between multiple endpoints can be well estimated using observed data. The proposed Dunnett-Bonferroni-based parallel gatekeeping procedure relaxes the preceding assumptions by splitting type I error rate among families using the Bonferroni inequality. While it is potentially less powerful than a Dunnett-based procedure when both procedures are applicable, the power loss is very minimal. Our proposed method avoids assumptions that might be challenged by regulatory agencies and does so with virtually no cost. Moreover, in most cases this method is easier to implement compared with the Dunnett-based procedure.
本文提出了一种基于邓尼特-邦费罗尼的平行把关程序,用于多终点剂量反应临床试验。它遵循了德米特里延科等人(《药物统计学》,2006年;第5卷:19 - 28页)基于邓尼特的平行把关策略,但在临界值的计算上有所不同。基于邓尼特的平行把关程序的实施依赖于在典型临床试验中难以证明合理的假设,即(a)来自不同终点的检验统计量的联合分布可以用多元t分布近似,以及(b)多个终点之间的真实相关性可以使用观测数据得到很好的估计。所提出的基于邓尼特-邦费罗尼的平行把关程序通过使用邦费罗尼不等式在各个组间分配I型错误率,放宽了上述假设。虽然当两种程序都适用时,它可能比基于邓尼特的程序效力稍低,但效力损失非常小。我们提出的方法避免了可能受到监管机构质疑的假设,而且几乎没有成本。此外,在大多数情况下,与基于邓尼特的程序相比,这种方法更容易实施。